At a glance
ClinicalIndex Comparison RecordN/ACompleted· 482 enrolled
Drug / intervention
DiamondTemp Ablation catheter +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Controlled Clinical Evaluation of the DiamondTemp™ Ablation System for the Treatment of Paroxysmal Atrial Fibrillation
In Brief
A clinical study evaluating DiamondTemp Ablation catheter and TactiCath Quartz Ablation catheter for Paroxysmal Atrial Fibrillation and Atrial Fibrillation. Completed, enrolled 482 participants across 23 sites in 5 countries.
Detailed Summary
The purpose of the DIAMOND-AF study is to establish the safety and effectiveness of the DiamondTemp System for the treatment of drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation in patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Czechia, France, Italy, United States
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartNov 2017
First PostedNov 2017
Primary CompletionNov 2019
Study CompletionDec 2019
TodayJul 2026
First PostedNov 7, 2017
Enrollment StartNov 6, 2017
Primary CompletionNov 18, 2019
Study CompletionDec 3, 2019
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 8.7 years ago
Interventions
DiamondTemp Ablation catheterdevice
a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter
TactiCath Quartz Ablation catheterdevice
a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter